Evolent Health Inc. (NYSE:EVH) – Analysts at William Blair lowered their Q4 2016 earnings per share estimates for Evolent Health in a research report issued to clients and investors on Tuesday. William Blair analyst R. Daniels now expects that the firm will earn ($0.15) per share for the quarter, down from their prior estimate of ($0.14). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Evolent Health’s FY2017 earnings at ($0.32) EPS.
Several other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of Evolent Health from a “hold” rating to a “sell” rating in a research note on Wednesday. Jefferies Group set a $28.00 target price on shares of Evolent Health and gave the company a “buy” rating in a research note on Tuesday. Leerink Swann reiterated a “buy” rating on shares of Evolent Health in a research note on Wednesday. Canaccord Genuity set a $30.00 price target on shares of Evolent Health and gave the company a “buy” rating in a report on Wednesday, September 28th. Finally, FBR & Co boosted their price target on shares of Evolent Health from $24.00 to $26.00 and gave the company an “outperform” rating in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $22.50.
Shares of Evolent Health (NYSE:EVH) opened at 25.33 on Thursday. The firm’s 50 day moving average is $23.80 and its 200-day moving average is $18.37. The company’s market capitalization is $1.53 billion. Evolent Health has a 52-week low of $8.14 and a 52-week high of $26.84.
Evolent Health (NYSE:EVH) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. Evolent Health had a negative net margin of 76.55% and a negative return on equity of 5.04%. The company had revenue of $56.50 million for the quarter, compared to the consensus estimate of $51.96 million. During the same period in the previous year, the firm earned ($0.95) EPS. Evolent Health’s revenue was up 443.3% on a year-over-year basis.
In other news, General Counsel Jonathan Weinberg sold 10,339 shares of the company’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $21.54, for a total value of $222,702.06. Following the sale, the general counsel now owns 76,245 shares of the company’s stock, valued at approximately $1,642,317.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Board Co Advisory sold 317,712 shares of the company’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $22.50, for a total transaction of $7,148,520.00. Following the completion of the sale, the insider now directly owns 4,128,167 shares in the company, valued at approximately $92,883,757.50. The disclosure for this sale can be found here. 8.85% of the stock is currently owned by insiders.
Several large investors have recently bought and sold shares of EVH. Schwab Charles Investment Management Inc. raised its stake in Evolent Health by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,784 shares of the company’s stock valued at $822,000 after buying an additional 504 shares during the last quarter. Nationwide Fund Advisors raised its stake in Evolent Health by 8.5% in the second quarter. Nationwide Fund Advisors now owns 10,109 shares of the company’s stock valued at $194,000 after buying an additional 789 shares during the last quarter. Geode Capital Management LLC raised its stake in Evolent Health by 1.3% in the first quarter. Geode Capital Management LLC now owns 75,085 shares of the company’s stock valued at $792,000 after buying an additional 948 shares during the last quarter. American International Group Inc. raised its stake in Evolent Health by 14.9% in the second quarter. American International Group Inc. now owns 8,761 shares of the company’s stock valued at $168,000 after buying an additional 1,134 shares during the last quarter. Finally, Salem Investment Counselors Inc. raised its stake in Evolent Health by 12.9% in the second quarter. Salem Investment Counselors Inc. now owns 27,080 shares of the company’s stock valued at $520,000 after buying an additional 3,100 shares during the last quarter. 40.22% of the stock is currently owned by institutional investors and hedge funds.
Evolent Health Company Profile
Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.
Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.